Assesses the effectiveness of efgartigimod in CIDP, suggesting improved patient outcomes.
ADHERE REAL will assess the real-world effectiveness of subcutaneous (SC) efgartigimod PH20 at managing patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and describe their treatment journey and healthcare resource utilization.
No takes yet. Share an insight, caveat, or question.
Karam et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: